Non-invasive fetal RhD genotyping (4268 DK)

The program is used for external quality assurance of non-invasive fetal Rhesus D genotyping.
The target group is clinical immunology departments.

There is two rounds of 2 samples annually.
In 2024 there were 50 participants.

Reports are available at no later then 15 weekdays after the deadline for reporting results.

Here you find useful information about the program:

If you have any questions, please contact program coordinator chemist Morten Pedersen,